Tags

Type your tag names separated by a space and hit enter

Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
Cancer. 2004 Sep 15; 101(6):1414-9.C

Abstract

BACKGROUND

Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance.

METHODS

The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily x 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated.

RESULTS

Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyotype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis.

CONCLUSIONS

The regimen of idarubicin and ara-C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however.

Authors+Show Affiliations

Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx 10466, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

15368329

Citation

Karbasian-Esfahani, Merat, et al. "Idarubicin and Standard-dose Cytosine Arabinoside in Adults With Recurrent and Refractory Acute Lymphocytic Leukemia." Cancer, vol. 101, no. 6, 2004, pp. 1414-9.
Karbasian-Esfahani M, Wiernik PH, Novik Y, et al. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer. 2004;101(6):1414-9.
Karbasian-Esfahani, M., Wiernik, P. H., Novik, Y., Paietta, E., & Dutcher, J. P. (2004). Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer, 101(6), 1414-9.
Karbasian-Esfahani M, et al. Idarubicin and Standard-dose Cytosine Arabinoside in Adults With Recurrent and Refractory Acute Lymphocytic Leukemia. Cancer. 2004 Sep 15;101(6):1414-9. PubMed PMID: 15368329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. AU - Karbasian-Esfahani,Merat, AU - Wiernik,Peter H, AU - Novik,Yelena, AU - Paietta,Elisabeth, AU - Dutcher,Janice P, PY - 2004/9/16/pubmed PY - 2004/9/29/medline PY - 2004/9/16/entrez SP - 1414 EP - 9 JF - Cancer JO - Cancer VL - 101 IS - 6 N2 - BACKGROUND: Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. METHODS: The current study evaluated the efficacy of a regimen comprising intravenous bolus injections of idarubicin, 12 mg/m2 daily x 3, and a continuous 7-day infusion of cytosine arabinoside (ara-C), 100 mg/m2 daily, in adults with refractory or recurrent ALL. Twenty patients aged 14-75 years were treated. RESULTS: Six patients (30%) achieved complete remission (CR), 5 (25%) had a partial response (PR), and 9 (45%) did not respond. Recovery of blood counts occurred at a median of 20 days. One patient who achieved CR and one who achieved PR survived 1.5 and 2 years, respectively, after receiving this treatment. The median response and overall survival periods were 2.75 and 6.3 months, respectively. There was no relation between remission duration and previous chemotherapy. Neither leukocyte count at study entry nor patient karyotype was associated with attainment of CR. All patients experienced profound myelosuppression. Gastrointestinal toxicity was mild to moderate, with the exception of one case of World Health Organization Grade 3 mucositis. CONCLUSIONS: The regimen of idarubicin and ara-C achieved a 55% overall response rate in patients with recurrent or refractory ALL. This response rate compared favorably with other regimens and was achieved with acceptable toxicity. Response duration was disappointing, however. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/15368329/Idarubicin_and_standard_dose_cytosine_arabinoside_in_adults_with_recurrent_and_refractory_acute_lymphocytic_leukemia_ L2 - https://doi.org/10.1002/cncr.20494 DB - PRIME DP - Unbound Medicine ER -